The market’s romance with BioNTech has been building for weeks, fueled by a leadership handover, a sympathetic rally from rival mRNA developers, and the promise of pivotal oncology data. But the German biotech now enters a stretch where anticipation must give way to proof — and where a long-simmering legal dispute refuses to fade into the background.
Shares were changing hands at roughly €96–98 in recent sessions, a level that still leaves them about 7–9 percent shy of the €105.80 52-week peak touched back in January. The stock’s run has been nothing if not assertive: it now trades about 17 percent above its 50-day moving average of €82.47 and roughly 15 percent above the 200-day line at €84.02. That technical stretch, however, cuts both ways — with a 30-day annualized volatility reading of 66 percent, the tape is primed for sharp moves in either direction once fresh catalysts land.
The Seoul Data Drop
The immediate focus is the World Conference on Lung Cancer, running September 12–15 in Seoul. BioNTech has committed to unveiling first-ever global Phase 1/2 data there on the combination of its bispecific candidate Pumitamig with the antibody-drug conjugate Elfetabart Drozuntecan in advanced lung cancer. Management has been careful to frame the disclosure as a historic first: no PD-(L)1xVEGF bispecific immunomodulator has previously been paired with an ADC in this setting on a global stage.
The same conference will also bring updated overall survival figures from the Phase 3 PRESERVE-003 study evaluating Gotistobart in patients with squamous non-small cell lung cancer who have already received prior treatment. A positive readout there would bolster the case that Gotistobart can differentiate itself from established PD-(L)1 therapies.
These presentations represent the first genuine test of whether the rally — which has largely been built on announcements rather than clinical substance — can be sustained. The stakes are considerable. Convincing efficacy and a manageable safety profile for the Pumitamig-ADC pairing would validate the broader oncology strategy and potentially expand the pipeline’s appeal beyond the six pivotal studies already underway. A miss, by contrast, would expose the valuation to a rapid recalibration toward the fundamentals: shrinking vaccine revenue and rising research costs.
A Legal Overhang That Won’t Lift
Complicating the narrative is the patent litigation that Arbutus Biopharma and Genevant Sciences have pressed against BioNTech and Pfizer over the lipid nanoparticle technology underpinning COMIRNATY. Arbutus signaled its resolve this week by launching a $230 million share buyback while confirming it would continue the legal fight. The cases, pending before Canada’s Federal Court and the Unified Patent Court, have yet to yield a decision — and the financial exposure, if BioNTech loses, remains unquantified.
Should investors sell immediately? Or is it worth buying BioNTech?
The timing is awkward for another reason. The LNP platform at the heart of the dispute is not merely a relic of the pandemic era; it is also integral to the delivery of mRNA-based oncology candidates that form the core of BioNTech’s future. A negative ruling could mean additional licensing costs or restrictions that reach beyond the shrinking vaccine franchise.
Wall Street Splits on the Setup
The analyst community has responded to the convergence of catalysts with divergent moves. Morgan Stanley issued a buy recommendation with a $115 price target on August 17, arguing the oncology story can offset the ongoing decline in vaccine sales. Canaccord Genuity went further, lifting its target to $142 while pointing to a cash reserve of €16.6 billion as a buffer against the legal uncertainty.
Yet the same week brought a more cautious chorus: Citigroup, Evercore ISI, and Berenberg all trimmed their price targets to $125, $130, and $132 respectively, even as they maintained positive ratings. The message from that camp was that the recent share surge — partly fueled by Merck and Moderna’s mid-August success with a personalized mRNA melanoma vaccine, which the market read as validation for the entire mRNA oncology approach — had already pulled forward some of the upside.
What September Will Settle
The company’s own guidance adds another layer of pressure. BioNTech has trimmed its 2026 revenue outlook to €1.6–1.9 billion, while research and development spending climbs on the oncology and ADC programs plus the integration of CureVac activities acquired late last year. The Q3 earnings report on November 2 will offer the next financial checkpoint after the conference season.
For now, the bull case rests on a straightforward proposition: if the Seoul data holds up, the stock’s relative strength against its moving averages is justified, and the three additional late-stage readouts promised for later this year could extend the momentum. The bear case is equally simple — the market has already paid handsomely for promises, and the patent dispute adds a binary risk that no amount of clinical optimism can fully neutralize.
September, then, is shaping up as a two-front test: whether the oncology pipeline can deliver on its billing, and whether the legal foundation beneath the platform can withstand scrutiny. The market has been generous with its advance credit. Now comes the reckoning.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from August 26 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 26.
BioNTech: Buy or sell? Read more here...
